RNA editing represents a transformative approach in gene therapy that modifies RNA transcripts to restore protein function without permanently altering the genome. Unlike DNA-based gene editing (CRISPR-Cas9, base editing), RNA editing offers transient effects, reduced off-target concerns, and the ability to repeat dosing — making it particularly attractive for chronic neurological conditions where long-term modulation may be needed.
RNA editing represents a transformative approach in gene therapy that modifies RNA transcripts to restore protein function without permanently altering the genome. Unlike DNA-based gene editing (CRISPR-Cas9, base editing), RNA editing offers transient effects, reduced off-target concerns, and the ability to repeat dosing — making it particularly attractive for chronic neurological conditions where long-term modulation may be needed.
The field has advanced rapidly since 2019, with multiple companies advancing programs toward clinical development. RNA editing can correct disease-causing point mutations, restore protein expression levels, and modulate RNA splicing — all through targeted modification of messenger RNA (mRNA) rather than DNA.
Mechanism: Adenosine Deaminases Acting on RNA (ADAR) enzymes catalyze the deamination of adenosine to inosine in double-stranded RNA. Since inosine is read as guanosine by the translation machinery, this results in an A→G amino acid change at the protein level.
Advantages:
| Company | Platform | Focus Areas | Status |
|---------|----------|-------------|--------|
| ProMis Neuroscience | ADAR | SCN1A (Dravet), others | Preclinical |
| Shape Therapeutics | RNA editing | CNS, genetic diseases | Preclinical |
| Rewind Therapeutics | ADAR | Neurological diseases | Preclinical |
| Korro Bio | ADAR | CNS, hepatic diseases | Preclinical |
| Ascidian Therapeutics | RNA editing | Multiple | Preclinical |
Mechanism: Engineered guide RNAs that recruit endogenous ADAR enzymes to specific target sites. The guide RNA forms a double-stranded structure with the target transcript, enabling site-specific deamination without requiring delivery of foreign editing proteins.
Advantages:
Mechanism: CRISPR-Cas13 systems (Cas13a, Cas13b, Cas13d) can be programmed to target specific RNA transcripts. Unlike ADAR-mediated editing, Cas13-based approaches can install any desired edit (not limited to A→G) and can also enable RNA knockdown through collateral activity.
Cas13 Variants:
| System | Characteristics | Applications |
|--------|-----------------|--------------|
| Cas13a (C2c2) | Bacterial RNase, collateral activity | RNA knockdown |
| Cas13b | Compact, no collateral | Precision editing |
| Cas13d (RfxCas13d) | Most compact, high efficiency | CNS delivery focus |
Advantages:
Mechanism: Cytidine deaminases (APOBEC1, APOBEC3 family) can convert cytidine to uridine, enabling C→T (or G→A at DNA level) corrections. This expands the reach of RNA editing to approximately 50% of pathogenic missense mutations when combined with A→I editing.
Companies exploring:
RNA editing therapies for neurological diseases face significant delivery challenges that differ from peripheral targets:
| Approach | Status | Notes |
|----------|--------|-------|
| Intrathecal injection | Clinical | Bypasses BBB, used for nusinersen |
| Intracisternal/magna injection | Preclinical | Direct CNS delivery |
| Focused ultrasound + microbubbles | Phase 1-2 | Transient BBB opening |
| AAV-delivered editors | Preclinical | Long-term expression |
| LNP-mRNA delivery | Preclinical | Transient expression |
| Exosome delivery | Research | Manufacturing challenges |
| Delivery Method | Duration | Redosability | Immunogenicity | CNS Penetration |
|----------------|----------|--------------|----------------|-----------------|
| Direct CNS injection | Long | Limited | Low | High |
| AAV editor | Long | Poor | Moderate | Moderate |
| LNP-mRNA | Short | Excellent | Low | Low (without FUS) |
| Exosomes | Medium | Good | Very Low | Moderate |
| ASO (repeat dosing) | Short | Excellent | Low | Moderate (intrathecal) |
RNA editing is particularly promising for neurodevelopmental epilepsies:
Dravet Syndrome (SCN1A):
| Feature | ASO | AAV Gene Therapy | DNA Base Editing | RNA Editing |
|---------|-----|------------------|-------------------|--------------|
| Duration | Weeks-months | Years | Permanent | Days-weeks |
| Redosability | Excellent | Poor | Not needed | Excellent |
| Immunogenicity | Low | Moderate | Moderate | Low |
| Variant coverage | Splice/modulation | Full gene | All point mutations | A→G (ADAR) |
| Delivery complexity | Moderate | High | High | Moderate |
| Safety profile | Well-characterized | Established | Emerging | Favorable |
| Regulatory precedent | Multiple approved | Several approved | First approvals 2023 | None yet |
| Manufacturing | Synthetic, scalable | Complex (viral) | Complex | Moderate |
| Indication | Target | Approach | Estimated Timeline |
|------------|--------|----------|---------------------|
| Dravet syndrome | SCN1A | ADAR | 2027-2028 IND |
| Angelman syndrome | UBE3A | ADAR/ASO | 2028-2029 |
| Huntington's disease | HTT | ASO/ADAR | 2026-2027 IND |
| Genetic epilepsy | Various | ADAR | 2028-2029 |
| CNS disorders | Multiple | Various | Research |
As of 2026, no RNA editing therapeutics have reached clinical trials for CNS indications. The field is following the ASO and AAV pathways:
NDEs present unique opportunities for RNA editing:
| Safety Concern | RNA Editing | DNA Editing |
|----------------|-------------|-------------|
| Off-target editing | Lower risk | Higher risk |
| Immunogenicity | Lower (no foreign protein for ADAR) | Moderate |
| Germline editing | Not possible | Theoretical risk |
| Long-term consequences | Reversible | Permanent |
Focus: ADAR-mediated RNA editing for neurological diseases
Programs: SCN1A (Dravet), others
Status: Preclinical
Platform: LEAD™ (Ligand-directed ADAR editing)
Focus: RNA editing platform for genetic diseases
Programs: CNS, others
Status: Preclinical
Technology: Proprietary RNA editing enzymes
Focus: ADAR-mediated editing for neurological diseases
Programs: Various CNS targets
Status: Preclinical
Focus: ADAR-based RNA editing
Programs: CNS, hepatic diseases
Status: Preclinical
Platform: OPERA™ (Oligonucleotide Promoted Editing of RNA)
Focus: RNA editing using trans-splicing
Programs: Multiple
Status: Preclinical
Approach: Replaces entire exons via RNA trans-splicing
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: